PT - JOURNAL ARTICLE AU - Eleni Bellou AU - Elli Keramida AU - Irma Bracka AU - Ioannis Karampinis AU - Andreas Paraskevas AU - Christina Gkriniouk AU - Despoina Zorpidou AU - Panagiotis Demertzis AU - Georgia Hardavella TI - Clinical effectiveness of recommended antibiotics in COVID19 pneumonias; assessing national referral centre guidance AID - 10.1183/13993003.congress-2021.PA3679 DP - 2021 Sep 05 TA - European Respiratory Journal PG - PA3679 VI - 58 IP - suppl 65 4099 - http://erj.ersjournals.com/content/58/suppl_65/PA3679.short 4100 - http://erj.ersjournals.com/content/58/suppl_65/PA3679.full SO - Eur Respir J2021 Sep 05; 58 AB - Introduction: Even though COVID19 can result in a wide disease spectrum, the pandemic has increased admissions of patients fulfilling the criteria for community-acquired pneumonia.Aim: To compare the clinical effectiveness of recommended dual antibiotics(abx) (ceftriaxone/azithromycin-CFX/AZ, ceftriaxone/moxifloxacin, CFX/MOX) in abx naive COVID19 pneumonia patients as per local guidance in a tertiary national referral centre.Materials/Methods: Retrospective review of all patient records with COVID19-pneumonia admitted during 03/2020-01/2021. Correlation of dual abx use with mortality, hospital stay, time to negative PCR test, intubation.Results: During 03/2020-01/2021, 160 patients were admitted;88.75% had COVID19 pneumomia(42% females, mean age 63years). On admission, 78% (125/160) patients received CFX of which 54% (67/125) received additionally MOX (group A) and 27%(34/125) AZ (group B). The remaining patients were excluded(not abx naïve). 27% of Group A and 11% of Group B were high risk in quick COVID severity index. Intubation occurred in 7.5% (5/67) in Group A and 8.8% (3/34) in Group B and intubation related mortality was 0%. Overall mortality was 7.4% in Group A and 8.8% in Group B (p<0.05 adjusting for clinical severity). Mean time to PCR nasopharyngeal test negativity was 16 days for Group A and 19 days for Group B (p<0.05). Mean hospital stay was 18 days for both groups.Conclusion: Patients on CFX/MOX achieved PCR negativity faster and managed to avoid intubation accounting for disease severity in comparison with patients on CFX/AZ. Mortality rates appear similar in both groups favouring CFX/moxifloxacin when adjusting for disease severity.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3679.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).